Molnupiravir

Molnupiravir is a medication used to treat mild to moderate COVID-19 in people at high risk of severe illness. It helps reduce the severity of symptoms and lowers the risk of hospitalisation when taken early in the course of infection. If you’ve been prescribed molnupiravir, here’s what you need to know.

What is molnupiravir?

Molnupiravir is an antiviral medication that helps stop the SARS-CoV-2 virus (which causes COVID-19) from multiplying in the body.

Find your prescription medicine

Sign up in seconds to easily manage your prescription medicine and we’ll even remind you when it’s time to take or reorder it!

How does molnupiravir work?

Molnupiravir introduces errors into the virus’s genetic material, preventing it from replicating effectively and reducing the severity of the infection.

What is molnupiravir used to treat?

Molnupiravir is commonly prescribed for:

  • Mild to moderate COVID-19 in adults who are at high risk of developing severe illness
  • Reducing the risk of hospitalisation and severe outcomes in vulnerable individuals

Who can take molnupiravir?

Molnupiravir is suitable for most adults with COVID-19 who are at high risk, as prescribed by a doctor.

Who might not be able to take molnupiravir?

Molnupiravir may not be suitable if you:

  • Are pregnant or planning to conceive
  • Are breastfeeding
  • Have severe liver or kidney disease
  • Are taking certain medications that may interact with antivirals

Can I take molnupiravir if I’m pregnant or breastfeeding?

Molnupiravir is not recommended during pregnancy or breastfeeding, as its effects on unborn babies and infants are not fully understood. Women of childbearing age should use effective contraception during treatment and for a period after stopping the medication, as advised by their doctor.

What if I miss a dose?

If you forget a dose, take it as soon as you remember unless it is close to your next dose. Do not take two doses at once.

How effective is molnupiravir?

Molnupiravir is highly effective at reducing the severity of COVID-19 when taken within five days of symptom onset.

What should I do if I take too much?

Taking too much molnupiravir may increase the risk of side effects. If you think you’ve taken too much, seek medical advice immediately.

What dose of molnupiravir is usually taken?

  • Standard dose: 800mg (four 200mg capsules) twice daily for five days

Your doctor will determine the correct dose based on your health status.

Powered by pharmacies

With over 1,700 pharmacy partners across the UK, you can get the help you need, wherever you are based.

Our website and mobile app make it easy and convenient to manage your health needs and book services at a pharmacy nearby.

What are the side effects of molnupiravir?

Common side effects include:

  • Diarrhoea
  • Nausea
  • Dizziness
  • Headache

Serious side effects are rare, but if you experience severe symptoms or an allergic reaction, seek urgent medical attention.

How should I take molnupiravir?

Molnupiravir is taken as oral capsules, swallowed whole with water.

When should molnupiravir be taken?

Molnupiravir should be taken as soon as possible after a confirmed COVID-19 diagnosis, ideally within five days of symptom onset.

What are the brand names for molnupiravir?

Molnupiravir is available under the brand name:

  • Lagevrio

Final thoughts

Molnupiravir is an effective treatment for COVID-19 in high-risk individuals, but it should be taken exactly as prescribed. If side effects occur or symptoms worsen, speak to your doctor or pharmacist.

Always consult a medical professional
This article is for informational purposes only and is not a substitute for medical advice. Always consult a healthcare professional before starting, stopping or changing any medication. If you have concerns about your medication or experience side effects, speak to your doctor or pharmacist immediately.

Download the app

Order prescriptions, book services, explore treatments and more, from your phone

download the healthera app
QR code link: https://healthera.app.link/x3gHGaQ5Otb